Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.52 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 11/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858105 | 1.00 | MET (0.52) | METMAP3K12JAK2BRD4ALK | |
| SCHEMBL16212180 | 1.00 | MET (0.52) | METMAP3K12JAK2BRD4ALK | |
| SCHEMBL26917087 | 1.00 | MET (0.52) | METMAP3K12JAK2BRD4ALK | |
| SCHEMBL29858142 | 1.00 | MET (0.52) | METMAP3K12JAK2BRD4ALK | |
| SCHEMBL26916404 | 0.83 | MET (0.53) | METMAP3K12JAK2ALKJAK1 | |
| SCHEMBL26916400 | 0.83 | MET (0.53) | METMAP3K12JAK2ALKJAK1 | |
| SCHEMBL26916761 | 0.83 | MET (0.51) | METMAP3K12JAK2ALKKMO | |
| SCHEMBL26916645 | 0.83 | MET (0.51) | METMAP3K12JAK2ALKKMO | |
| SCHEMBL29857638 | 0.83 | MET (0.51) | METMAP3K12JAK2ALKKMO | |
| SCHEMBL24133538 | 0.82 | BRD4 (0.40) | MAP3K12BRD4KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | MET 3075/4885MAP3K12 14/4885JAK2 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.